<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868099</url>
  </required_header>
  <id_info>
    <org_study_id>531-CN002</org_study_id>
    <nct_id>NCT02868099</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>A Multi-center, Randomized, Placebo-controlled, Double-blinded Then Open 2 Stages Clinical Trial to Evaluate the Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin China Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin China Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the efficacy and safety of romiplostim for injection in adlut&#xD;
      subjects with persistent or chronic primary immune thrombocytopenia (ITP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multi-center, Randomized, Placebo-controlled, Double-blinded then Open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Placebo-controlled, Double-blinded then Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of weeks in which the platelet response counts increase above 50×10^9/L</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose platelet counts relative to the baseline increase ≥ 20×10^9/L</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have received emergency treatment to increase the platelet counts</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received placebo for injection treatment will be administered subcutaneously once a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with immune thrombocytopenia (ITP) for at least 6 months prior to signing&#xD;
             the informed consent form (ICF).&#xD;
&#xD;
          -  Subject is ≥ 18 years old while signing the ICF.&#xD;
&#xD;
          -  Patients who have no response or relapsed after splenectomy. Or patients who have not&#xD;
             been splenectomised and have no response or relapse to at least 1 prior treatment for&#xD;
             immune thrombocytopenia (ITP).&#xD;
&#xD;
          -  The mean of 3 scheduled platelet counts taken during the screening period must be: &lt;&#xD;
             30 ×10^9/L, with none &gt;35×10^9/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known history of bone marrow stem cell disorder. Any abnormal bone marrow findings&#xD;
             other than those typical of ITP.&#xD;
&#xD;
          -  Any active malignancy. If prior history of cancer other than basal cell carcinoma or&#xD;
             cervical carcinoma in situ, and no treatment or active disease within 5 years prior to&#xD;
             signing the ICF..&#xD;
&#xD;
          -  Received hematopoietic growth factors (e.g., granulocyte colony-stimulating factor,&#xD;
             macrophage colony-stimulating factor, erythropoietin, interleukin-11) for any reason&#xD;
             within 4 weeks prior to signing the ICF.&#xD;
&#xD;
          -  Received myeloproliferative leukemia (MPL) stimulation product other than the subject&#xD;
             who had suspended recombinant human thrombopoietin (rHuTPO) for injection for 4 weeks&#xD;
             before signing ICF.&#xD;
&#xD;
          -  Received any anti-malignancy agents (e.g., cyclophosphamide, 6-mercaptopurine,&#xD;
             vincristine, vinblastine, Interferon-alfa) for any reason within 8 weeks prior to&#xD;
             signing the ICF.&#xD;
&#xD;
          -  Received any monoclonal antibody drugs (e.g., rituximab) for any reason within 14&#xD;
             weeks prior to signing the ICF.&#xD;
&#xD;
          -  Less than 4 weeks since end of any clinical trials about therapeutic drug or device&#xD;
             prior to signing the ICF.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  In the opinions of the principal investigator or investigators, the patients are not&#xD;
             suitable for participation in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peking Union Medical College Hospital,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

